Alimentiv and Dova Health Intelligence (Previously Satisfai Health Inc.) Launch an AI Solution for Scoring of Ulcerative Colitis (UC) at DDW 2025 in San Diego
1.5.2025 13:30:00 CEST | Business Wire | Press Release
Alimentiv, a global full-service GI contract research organization (CRO) providing clinical trials, medical imaging, and precision medicine services to the pharmaceutical and biotechnology industries, and Dova Health Intelligence™ (formerly Satisfai Health), a Vancouver-based software company focused on the application of artificial intelligence to gastrointestinal disease assessment, are announcing the commercial availability of Dova Health’s DovaVision™,an AI-powered dynamic frame-level Mayo Endoscopic Sub-score (MES) feature analysis solution of endoscopy videos, providing adjunct AI-reads for Phase I through IV UC clinical trials.
With DovaVision™, researchers and sponsors have access to enhanced endoscopic evaluation and interpretation, improving the depth of imaging data generated, leading to deeper insights in UC research and clinical development programs. Dova’s technology was designed and built for purpose using a comprehensive global dataset of anonymized IBD colonoscopy videos, incorporating data labelling and clinical insights from Alimentiv’s global leading central readers and medical experts on IBD disease assessment and scoring within UC clinical trials. “In the era of precision medicine, successful clinical trials require more than central reader generated categorical scores — they need deeper, data-driven insights. With DovaVision™, we’re applying explainable AI to endoscopy video data to reveal additional understanding of gastrointestinal disease activity and treatment response,” said Solveig Johannessen, CEO of Dova Health Intelligence™.
“By detecting and quantifying subtle changes in endoscopic disease activity, DovaVision™ goes beyond manual scoring to deliver consistent, frame-level analysis of UC endoscopy videos. Its raw data outputs can integrate with other clinical datasets, enabling researchers and sponsors to correlate visual imaging biomarkers with patient outcomes to provide mechanistic insights. As a gastroenterologist, I know this will make a big difference in clinical trials,” said Dr. Michael Byrne, founder and chairman of Dova.
“We are very excited to bring this enhanced video analysis capability into Alimentiv’s medical imaging portfolio. In making this exciting new AI technology available for our sponsors, they will continue to lead the industry with more detailed analysis, competitive trial costs, and faster timelines,” said Pierre Gaudreault, CEO, Alimentiv.
DovaVision™ is intended for research use only and is being made available within Alimentiv’s proprietary multi-modal imaging review platform, Notō™, offering a unique end-to-end solution for medical image-based analysis and scoring. DovaVision™ is not a medical device and is not intended to be used by healthcare professionals for clinical decision making, diagnosis, or for the provision of patient care.
About Alimentiv, Inc.
Alimentiv is a leading specialty GI-focused CRO, advancing frontiers of gastrointestinal (GI) clinical trials and medical research since 1986. As a global CRO offering clinical, medical imaging and precision medicine services and solutions, Alimentiv partners with pharmaceutical and biotechnology industries to advance the development of novel therapies and accelerate their time to market. Alimentiv is headquartered in London, Ontario, Canada, with a global footprint across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. Learn more: alimentiv.com
About Dova Health Intelligence Inc.
Dova Health Intelligence™ is a precision health technology company advancing gastrointestinal (GI) care and research through AI-powered solutions. Specializing in computer vision and data-driven diagnostics, Dova develops tools that enhance clinical decision-making, support pharmaceutical innovation, and improve patient outcomes. With a strong foundation in GI-focused modalities like endoscopy and ultrasound, Dova is expanding globally with a growing suite of scalable, intelligent products—such as DovaVision™ (formerly Certai) and DovaSound (formerly Sonai). Headquartered in Canada, Dova collaborates with leading researchers, clinicians, and industry partners to deliver actionable insights where they matter most. Learn more: dovahealth.ca
View source version on businesswire.com: https://www.businesswire.com/news/home/20250501294949/en/
Contacts
MEDIA CONTACT:
Gabe Martinez
+1 308-338-2304
pr@scorrmarketing.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom